ID   FGFR4_HUMAN             Reviewed;         802 AA.
AC   P22455; G3JVM2; G3JVM5; G3JVM7; G3JVM9; O43785; Q14309; Q71TW8; Q8TDA0;
AC   Q96KE5;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   27-APR-2001, sequence version 2.
DT   12-OCT-2022, entry version 232.
DE   RecName: Full=Fibroblast growth factor receptor 4;
DE            Short=FGFR-4;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD334;
DE   Flags: Precursor;
GN   Name=FGFR4; Synonyms=JTK2, TKF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1709094; DOI=10.1002/j.1460-2075.1991.tb07654.x;
RA   Partanen J.M., Maekelae T.P., Eerola E., Korhonen J., Hirvonen H.,
RA   Claesson-Welsh L., Alitalo K.;
RT   "FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct
RT   expression pattern.";
RL   EMBO J. 10:1347-1354(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS RECEPTOR FOR FGF1
RP   AND FGF2.
RC   TISSUE=Mammary gland;
RX   PubMed=7680645; DOI=10.1016/s0021-9258(18)53334-2;
RA   Ron D., Reich R., Chedid M., Lengel C., Cohen O.E., Chan A.M., Neufeld G.,
RA   Miki T., Tronick S.R.;
RT   "Fibroblast growth factor receptor 4 is a high affinity receptor for both
RT   acidic and basic fibroblast growth factor but not for keratinocyte growth
RT   factor.";
RL   J. Biol. Chem. 268:5388-5394(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT LEU-136, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Intestine;
RX   PubMed=10631118; DOI=10.1006/bbrc.1999.2010;
RA   Takaishi S., Sawada M., Morita Y., Seno H., Fukuzawa H., Chiba T.;
RT   "Identification of a novel alternative splicing of human FGF receptor 4:
RT   soluble-form splice variant expressed in human gastrointestinal epithelial
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 267:658-662(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9457674; DOI=10.1007/s003359900703;
RA   Kostrzewa M., Muller U.;
RT   "Genomic structure and complete sequence of the human FGFR4 gene.";
RL   Mamm. Genome 9:131-135(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS ILE-10 AND LEU-136,
RP   INVOLVEMENT IN CANCER, AND VARIANT ARG-388.
RX   PubMed=21882254; DOI=10.1002/mc.20848;
RA   Marshall A.D., van der Ent M.A., Grosveld G.C.;
RT   "PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.";
RL   Mol. Carcinog. 51:807-815(2012).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-136.
RA   Lind D.L., Cox D.R.;
RT   "Sequence variation in fibroblast growth factor receptors 3 and 4.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-10; LEU-136 AND
RP   ARG-388.
RG   NIEHS SNPs program;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-136.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 609-676.
RC   TISSUE=Blood;
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [12]
RP   RETRACTED PAPER.
RX   PubMed=11781352; DOI=10.1172/jci14036;
RA   Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.;
RT   "Targeted expression of a human pituitary tumor-derived isoform of FGF
RT   receptor-4 recapitulates pituitary tumorigenesis.";
RL   J. Clin. Invest. 109:69-78(2002).
RN   [13]
RP   RETRACTION NOTICE OF PUBMED:11781352.
RX   PubMed=26237043; DOI=10.1172/jci83399;
RA   Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.;
RL   J. Clin. Invest. 125:3303-3303(2015).
RN   [14]
RP   PROTEIN SEQUENCE OF 22-38.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [15]
RP   FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF SIGNALING VIA PLCG1 AND
RP   PIK3R1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-754, AND MUTAGENESIS
RP   OF TYR-754.
RX   PubMed=7518429; DOI=10.1016/s0021-9258(17)32309-8;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G., Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [16]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF6; FGF8 AND FGF9, AND FUNCTION IN
RP   CELL PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F.,
RA   Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [17]
RP   FUNCTION IN CELL DIFFERENTIATION, MUTAGENESIS OF LYS-503, CATALYTIC
RP   ACTIVITY, AND IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1; FRS2;
RP   SRC; SHC; GAP43 AND CTTN.
RX   PubMed=11433297; DOI=10.1038/35083041;
RA   Cavallaro U., Niedermeyer J., Fuxa M., Christofori G.;
RT   "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor
RT   signalling.";
RL   Nat. Cell Biol. 3:650-657(2001).
RN   [18]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=11830541;
RA   Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M.,
RA   Knyazeva T., Mueller S., Gaertner S., Sures I., Wang H., Imyanitov E.,
RA   Haering H.U., Knayzev P., Iacobelli S., Hoefler H., Ullrich A.;
RT   "Cancer progression and tumor cell motility are associated with the FGFR4
RT   Arg(388) allele.";
RL   Cancer Res. 62:840-847(2002).
RN   [19]
RP   INTERACTION WITH FGF1; FGF17; FGF18; FGF19; FGF21 AND FGF23, AND FUNCTION
RP   IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.m601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The complete
RT   mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [20]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN SIGNALING AND IN
RP   REGULATION OF CYP7A1 AND BILE ACID SYNTHESIS.
RX   PubMed=17623664; DOI=10.1074/jbc.m704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V.,
RA   Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [21]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   LYS-503, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the
RT   Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [22]
RP   INVOLVEMENT IN CANCER, AND VARIANT ARG-388.
RX   PubMed=18756523; DOI=10.1002/ijc.23578;
RA   Ma Z., Tsuchiya N., Yuasa T., Inoue T., Kumazawa T., Narita S.,
RA   Horikawa Y., Tsuruta H., Obara T., Saito M., Satoh S., Ogawa O.,
RA   Habuchi T.;
RT   "Polymorphisms of fibroblast growth factor receptor 4 have association with
RT   the development of prostate cancer and benign prostatic hyperplasia and the
RT   progression of prostate cancer in a Japanese population.";
RL   Int. J. Cancer 123:2574-2579(2008).
RN   [23]
RP   CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF PLCG1;
RP   FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ACTIVITY REGULATION, UBIQUITINATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18480409; DOI=10.1091/mbc.e07-12-1219;
RA   Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.;
RT   "Ubiquitination of fibroblast growth factor receptor 1 is required for its
RT   intracellular sorting but not for its endocytosis.";
RL   Mol. Biol. Cell 19:3390-3403(2008).
RN   [24]
RP   CATALYTIC ACTIVITY, FUNCTION AS FGF2 RECEPTOR AND IN STIMULATION OF CELL
RP   PROLIFERATION, SUBCELLULAR LOCATION, INTERACTION WITH FGF2 AND HIP1,
RP   PHOSPHORYLATION AT TYR-642 AND TYR-643, INVOLVEMENT IN CANCER, AND
RP   CHARACTERIZATION OF VARIANT ARG-388.
RX   PubMed=18670643; DOI=10.1593/neo.08450;
RA   Wang J., Yu W., Cai Y., Ren C., Ittmann M.M.;
RT   "Altered fibroblast growth factor receptor 4 stability promotes prostate
RT   cancer progression.";
RL   Neoplasia 10:847-856(2008).
RN   [25]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=20638838; DOI=10.1016/j.ejca.2010.06.017;
RA   Xu W., Li Y., Wang X., Chen B., Wang Y., Liu S., Xu J., Zhao W., Wu J.;
RT   "FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis
RT   including 8555 subjects.";
RL   Eur. J. Cancer 46:3332-3338(2010).
RN   [26]
RP   FUNCTION IN FGF19 SIGNALING AND IN REGULATION OF BILE ACID SYNTHESIS VIA
RP   CYP7A1, INTERACTION WITH FGF19; KL AND KLB, AUTOPHOSPHORYLATION,
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=20683963; DOI=10.1002/hep.23708;
RA   Triantis V., Saeland E., Bijl N., Oude-Elferink R.P., Jansen P.L.;
RT   "Glycosylation of fibroblast growth factor receptor 4 is a key regulator of
RT   fibroblast growth factor 19-mediated down-regulation of cytochrome P450
RT   7A1.";
RL   Hepatology 52:656-666(2010).
RN   [27]
RP   FUNCTION IN HEPATOCYTE PROLIFERATION AND FGF19 SIGNALING.
RX   PubMed=20018895; DOI=10.1074/jbc.m109.068783;
RA   Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R., Gupte J.,
RA   Hager T., Wang Z., Lindberg R., Li Y.;
RT   "FGF19-induced hepatocyte proliferation is mediated through FGFR4
RT   activation.";
RL   J. Biol. Chem. 285:5165-5170(2010).
RN   [28]
RP   FUNCTION IN DOWN-REGULATION OF MMP14, AUTOPHOSPHORYLATION, AND INTERACTION
RP   WITH MMP14.
RX   PubMed=20798051; DOI=10.1073/pnas.0914459107;
RA   Sugiyama N., Varjosalo M., Meller P., Lohi J., Chan K.M., Zhou Z.,
RA   Alitalo K., Taipale J., Keski-Oja J., Lehti K.;
RT   "FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a
RT   membrane type 1 matrix metalloproteinase-FGFR4 complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15786-15791(2010).
RN   [29]
RP   INVOLVEMENT IN CANCER, AND VARIANT ARG-388.
RX   PubMed=21349172; DOI=10.1186/1471-2407-11-84;
RA   Xu B., Tong N., Chen S.Q., Hua L.X., Wang Z.J., Zhang Z.D., Chen M.;
RT   "FGFR4 Gly388Arg polymorphism contributes to prostate cancer development
RT   and progression: a meta-analysis of 2618 cases and 2305 controls.";
RL   BMC Cancer 11:84-84(2011).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=21412156; DOI=10.1097/cej.0b013e3283457274;
RA   Frullanti E., Berking C., Harbeck N., Jezequel P., Haugen A., Mawrin C.,
RA   Parise O. Jr., Sasaki H., Tsuchiya N., Dragani T.A.;
RT   "Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer
RT   prognostic factor.";
RL   Eur. J. Cancer Prev. 20:340-347(2011).
RN   [32]
RP   FUNCTION IN FGF19 SIGNALING, FUNCTION IN STIMULATION OF CELL PROLIFERATION
RP   AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND INTERACTION WITH FGF19;
RP   KLB AND SULFATED GLYCOSAMINOGLYCANS.
RX   PubMed=21653700; DOI=10.1074/jbc.m111.251140;
RA   Nakamura M., Uehara Y., Asada M., Honda E., Nagai N., Kimata K., Suzuki M.,
RA   Imamura T.;
RT   "Sulfated glycosaminoglycans are required for specific and sensitive
RT   fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and
RT   betaKlotho.";
RL   J. Biol. Chem. 286:26418-26423(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   INTERACTION WITH STAT3, INVOLVEMENT IN CANCER, CHARACTERIZATION OF VARIANT
RP   ARG-388, AND PHOSPHORYLATION AT TYR-390.
RX   PubMed=26675719; DOI=10.1038/nature16449;
RA   Ulaganathan V.K., Sperl B., Rapp U.R., Ullrich A.;
RT   "Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding
RT   site.";
RL   Nature 528:570-574(2015).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-10; LEU-136; ALA-179; SER-426; ASN-516;
RP   MET-550; THR-712 AND ASN-772.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [37]
RP   REVIEW ON LIGAND SELECTIVITY AND SIGNALING.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [38]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [39]
RP   CHARACTERIZATION OF VARIANT ARG-388, AND FUNCTION IN TUMOR CELL INVASION.
RX   PubMed=20876804; DOI=10.1158/0008-5472.can-10-1223;
RA   Sugiyama N., Varjosalo M., Meller P., Lohi J., Hyytiainen M., Kilpinen S.,
RA   Kallioniemi O., Ingvarsen S., Engelholm L.H., Taipale J., Alitalo K.,
RA   Keski-Oja J., Lehti K.;
RT   "Fibroblast growth factor receptor 4 regulates tumor invasion by coupling
RT   fibroblast growth factor signaling to extracellular matrix degradation.";
RL   Cancer Res. 70:7851-7861(2010).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor
CC       for fibroblast growth factors and plays a role in the regulation of
CC       cell proliferation, differentiation and migration, and in regulation of
CC       lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D
CC       metabolism and phosphate homeostasis. Required for normal down-
CC       regulation of the expression of CYP7A1, the rate-limiting enzyme in
CC       bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and
CC       FRS2. Ligand binding leads to the activation of several signaling
CC       cascades. Activation of PLCG1 leads to the production of the cellular
CC       signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate.
CC       Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and
CC       SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the
CC       MAP kinase signaling pathway, as well as of the AKT1 signaling pathway.
CC       Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and
CC       its lysosomal degradation. FGFR4 signaling is down-regulated by
CC       receptor internalization and degradation; MMP14 promotes
CC       internalization and degradation of FGFR4. Mutations that lead to
CC       constitutive kinase activation or impair normal FGFR4 inactivation lead
CC       to aberrant signaling. {ECO:0000269|PubMed:11433297,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20018895,
CC       ECO:0000269|PubMed:20683963, ECO:0000269|PubMed:20798051,
CC       ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21653700,
CC       ECO:0000269|PubMed:7518429, ECO:0000269|PubMed:7680645,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:17311277,
CC         ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:18670643};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. Ligand binding leads to dimerization and activation by
CC       autophosphorylation on tyrosine residues.
CC       {ECO:0000269|PubMed:18480409}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with FGF1,
CC       FGF2, FGF4, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, FGF19, FGF21 and
CC       FGF23 (in vitro). Binding affinity for FGF family members is enhanced
CC       by interactions between FGFs and heparan sulfate proteoglycans.
CC       Interacts with KLB; this strongly increases the affinity for FGF19 and
CC       FGF23. Affinity for FGF19 is strongly increased by KLB and sulfated
CC       glycosaminoglycans. KLB and KL both interact with the core-glycosylated
CC       FGFR4 in the endoplasmic reticulum and promote its degradation, so that
CC       only FGFR4 with fully mature N-glycans is expressed at the cell
CC       surface. Identified in a complex with NCAM1, CDH2, PLCG1, FRS2, SRC,
CC       SHC1, GAP43 and CTTN. Interacts with MMP14 and HIP1 (PubMed:11433297,
CC       PubMed:16597617, PubMed:17623664, PubMed:18670643, PubMed:20683963,
CC       PubMed:20798051, PubMed:21653700, PubMed:7518429, PubMed:8663044).
CC       Interacts with STAT3 (PubMed:26675719). {ECO:0000269|PubMed:11433297,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20683963,
CC       ECO:0000269|PubMed:20798051, ECO:0000269|PubMed:21653700,
CC       ECO:0000269|PubMed:26675719, ECO:0000269|PubMed:7518429,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- INTERACTION:
CC       P22455; P11362: FGFR1; NbExp=3; IntAct=EBI-6256193, EBI-1028277;
CC       P22455; P50281: MMP14; NbExp=6; IntAct=EBI-6256193, EBI-992788;
CC       P22455; P07949: RET; NbExp=2; IntAct=EBI-6256193, EBI-2480756;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endosome. Endoplasmic reticulum. Note=Internalized from the
CC       cell membrane to recycling endosomes, and from there back to the cell
CC       membrane.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P22455-1; Sequence=Displayed;
CC       Name=2; Synonyms=Soluble-form;
CC         IsoId=P22455-2; Sequence=VSP_035108;
CC   -!- TISSUE SPECIFICITY: Expressed in gastrointestinal epithelial cells,
CC       pancreas, and gastric and pancreatic cancer cell lines.
CC       {ECO:0000269|PubMed:10631118}.
CC   -!- PTM: N-glycosylated. Full maturation of the glycan chains in the Golgi
CC       is essential for high affinity interaction with FGF19.
CC   -!- PTM: Ubiquitinated. Subject to proteasomal degradation when not fully
CC       glycosylated. {ECO:0000269|PubMed:18480409}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together with
CC       heparan sulfate proteoglycan or heparin promotes receptor dimerization
CC       and autophosphorylation on tyrosine residues. Autophosphorylation
CC       occurs in trans between the two FGFR molecules present in the dimer.
CC       {ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:18670643,
CC       ECO:0000269|PubMed:7518429}.
CC   -!- DISEASE: Note=FGFR4 variants may be involved in the pathogenesis of
CC       various cancers. Variant Arg-388 predisposes cancer patients to
CC       accelerated disease progression and may be associated with poor
CC       prognosis. It has been found in prostate cancer as well as cancers of
CC       the breast, colon, head and neck, larynx, lung, skin.
CC       {ECO:0000269|PubMed:11830541, ECO:0000269|PubMed:18670643,
CC       ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20638838,
CC       ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21349172,
CC       ECO:0000269|PubMed:21412156, ECO:0000269|PubMed:21882254,
CC       ECO:0000269|PubMed:26675719}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: An additional N-terminally truncated cytoplasmic isoform was
CC       previously reported to exist. However, the paper was subsequently
CC       retracted due to concerns regarding duplication of panels in some
CC       figures. {ECO:0000305|PubMed:11781352, ECO:0000305|PubMed:26237043}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr4/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR4ID512ch5q35.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X57205; CAA40490.1; -; mRNA.
DR   EMBL; L03840; AAB59389.1; -; mRNA.
DR   EMBL; AF202063; AAF27432.1; -; mRNA.
DR   EMBL; Y13901; CAA74200.1; -; Genomic_DNA.
DR   EMBL; AF359246; AAK51435.1; -; mRNA.
DR   EMBL; JN007471; AEO19712.1; -; mRNA.
DR   EMBL; JN007472; AEO19713.1; -; mRNA.
DR   EMBL; JN007473; AEO19714.1; -; mRNA.
DR   EMBL; JN007474; AEO19715.1; -; mRNA.
DR   EMBL; JN007475; AEO19716.1; -; mRNA.
DR   EMBL; JN007476; AEO19717.1; -; mRNA.
DR   EMBL; JN007477; AEO19718.1; -; mRNA.
DR   EMBL; JN007478; AEO19719.1; -; mRNA.
DR   EMBL; JN007479; AEO19720.1; -; mRNA.
DR   EMBL; JN007480; AEO19721.1; -; mRNA.
DR   EMBL; JN007481; AEO19722.1; -; mRNA.
DR   EMBL; JN007482; AEO19723.1; -; mRNA.
DR   EMBL; AF487555; AAM13666.1; -; Genomic_DNA.
DR   EMBL; EF571596; ABQ01235.1; -; Genomic_DNA.
DR   EMBL; AC027314; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471195; EAW85036.1; -; Genomic_DNA.
DR   EMBL; BC011847; AAH11847.1; -; mRNA.
DR   EMBL; M59373; AAA63208.1; -; mRNA.
DR   CCDS; CCDS4410.1; -. [P22455-1]
DR   CCDS; CCDS4411.1; -. [P22455-2]
DR   PIR; S15345; TVHUF4.
DR   RefSeq; NP_001278909.1; NM_001291980.1.
DR   RefSeq; NP_002002.3; NM_002011.4. [P22455-1]
DR   RefSeq; NP_075252.2; NM_022963.3. [P22455-2]
DR   RefSeq; NP_998812.1; NM_213647.2. [P22455-1]
DR   RefSeq; XP_005265895.1; XM_005265838.3.
DR   PDB; 4QQ5; X-ray; 2.20 A; A=445-753.
DR   PDB; 4QQC; X-ray; 2.40 A; A=445-753.
DR   PDB; 4QQJ; X-ray; 1.68 A; A=445-753.
DR   PDB; 4QQT; X-ray; 1.50 A; A=445-753.
DR   PDB; 4QRC; X-ray; 1.90 A; A=445-753.
DR   PDB; 4R6V; X-ray; 2.35 A; A=445-753.
DR   PDB; 4TYE; X-ray; 2.80 A; A=447-753.
DR   PDB; 4TYG; X-ray; 2.40 A; A=447-753.
DR   PDB; 4TYI; X-ray; 3.40 A; A=447-753.
DR   PDB; 4TYJ; X-ray; 2.45 A; A=447-753.
DR   PDB; 4UXQ; X-ray; 1.85 A; A=447-753.
DR   PDB; 4XCU; X-ray; 1.71 A; A=449-751.
DR   PDB; 5JKG; X-ray; 2.35 A; A=445-753.
DR   PDB; 5NUD; X-ray; 2.50 A; A/B=449-753.
DR   PDB; 5NWZ; X-ray; 2.37 A; A/B=449-753.
DR   PDB; 5XFF; X-ray; 2.70 A; A=445-753.
DR   PDB; 5XFJ; X-ray; 3.25 A; A=445-753.
DR   PDB; 6IUO; X-ray; 2.30 A; A=445-753.
DR   PDB; 6IUP; X-ray; 2.00 A; A=445-753.
DR   PDB; 6J6Y; X-ray; 2.15 A; A/D=141-244.
DR   PDB; 6JPE; X-ray; 1.60 A; A=445-753.
DR   PDB; 6JPJ; X-ray; 2.64 A; A=445-753.
DR   PDB; 6NVG; X-ray; 1.99 A; A=450-751.
DR   PDB; 6NVH; X-ray; 1.90 A; A=450-751.
DR   PDB; 6NVI; X-ray; 2.12 A; A=450-751.
DR   PDB; 6NVJ; X-ray; 2.30 A; A=450-751.
DR   PDB; 6NVK; X-ray; 2.30 A; A=450-751.
DR   PDB; 6V9C; X-ray; 1.90 A; A=449-751.
DR   PDB; 6YI8; X-ray; 2.13 A; A/B=447-753.
DR   PDB; 7DTZ; X-ray; 2.01 A; A=445-753.
DR   PDB; 7F3M; X-ray; 2.29 A; A=445-753.
DR   PDB; 7N1J; X-ray; 2.99 A; A/C=245-355.
DR   PDB; 7V29; X-ray; 1.98 A; A/B=445-753.
DR   PDB; 7VJL; X-ray; 2.90 A; A/B=453-753.
DR   PDB; 7WCT; X-ray; 2.11 A; A=445-753.
DR   PDB; 7WCW; X-ray; 2.32 A; A=445-753.
DR   PDB; 7WCX; X-ray; 2.17 A; A=445-753.
DR   PDBsum; 4QQ5; -.
DR   PDBsum; 4QQC; -.
DR   PDBsum; 4QQJ; -.
DR   PDBsum; 4QQT; -.
DR   PDBsum; 4QRC; -.
DR   PDBsum; 4R6V; -.
DR   PDBsum; 4TYE; -.
DR   PDBsum; 4TYG; -.
DR   PDBsum; 4TYI; -.
DR   PDBsum; 4TYJ; -.
DR   PDBsum; 4UXQ; -.
DR   PDBsum; 4XCU; -.
DR   PDBsum; 5JKG; -.
DR   PDBsum; 5NUD; -.
DR   PDBsum; 5NWZ; -.
DR   PDBsum; 5XFF; -.
DR   PDBsum; 5XFJ; -.
DR   PDBsum; 6IUO; -.
DR   PDBsum; 6IUP; -.
DR   PDBsum; 6J6Y; -.
DR   PDBsum; 6JPE; -.
DR   PDBsum; 6JPJ; -.
DR   PDBsum; 6NVG; -.
DR   PDBsum; 6NVH; -.
DR   PDBsum; 6NVI; -.
DR   PDBsum; 6NVJ; -.
DR   PDBsum; 6NVK; -.
DR   PDBsum; 6V9C; -.
DR   PDBsum; 6YI8; -.
DR   PDBsum; 7DTZ; -.
DR   PDBsum; 7F3M; -.
DR   PDBsum; 7N1J; -.
DR   PDBsum; 7V29; -.
DR   PDBsum; 7VJL; -.
DR   PDBsum; 7WCT; -.
DR   PDBsum; 7WCW; -.
DR   PDBsum; 7WCX; -.
DR   AlphaFoldDB; P22455; -.
DR   SMR; P22455; -.
DR   BioGRID; 108555; 226.
DR   CORUM; P22455; -.
DR   DIP; DIP-5149N; -.
DR   IntAct; P22455; 332.
DR   MINT; P22455; -.
DR   STRING; 9606.ENSP00000292408; -.
DR   BindingDB; P22455; -.
DR   ChEMBL; CHEMBL3973; -.
DR   DrugBank; DB12147; Erdafitinib.
DR   DrugBank; DB01109; Heparin.
DR   DrugBank; DB11886; Infigratinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB15102; Pemigatinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugCentral; P22455; -.
DR   GuidetoPHARMACOLOGY; 1811; -.
DR   TCDB; 8.A.23.1.9; the basigin (basigin) family.
DR   GlyConnect; 1938; 7 N-Linked glycans (4 sites).
DR   GlyGen; P22455; 8 sites, 7 N-linked glycans (4 sites), 1 Thr glycan (1 site).
DR   iPTMnet; P22455; -.
DR   PhosphoSitePlus; P22455; -.
DR   BioMuta; FGFR4; -.
DR   DMDM; 13432140; -.
DR   CPTAC; CPTAC-1768; -.
DR   EPD; P22455; -.
DR   jPOST; P22455; -.
DR   MassIVE; P22455; -.
DR   MaxQB; P22455; -.
DR   PaxDb; P22455; -.
DR   PeptideAtlas; P22455; -.
DR   PRIDE; P22455; -.
DR   ProteomicsDB; 53990; -. [P22455-1]
DR   ProteomicsDB; 53991; -. [P22455-2]
DR   ABCD; P22455; 1 sequenced antibody.
DR   Antibodypedia; 3922; 876 antibodies from 44 providers.
DR   DNASU; 2264; -.
DR   Ensembl; ENST00000292408.9; ENSP00000292408.4; ENSG00000160867.15. [P22455-1]
DR   Ensembl; ENST00000393637.5; ENSP00000377254.1; ENSG00000160867.15. [P22455-2]
DR   Ensembl; ENST00000502906.5; ENSP00000424960.1; ENSG00000160867.15. [P22455-1]
DR   GeneID; 2264; -.
DR   KEGG; hsa:2264; -.
DR   MANE-Select; ENST00000292408.9; ENSP00000292408.4; NM_213647.3; NP_998812.1.
DR   UCSC; uc003mfl.4; human. [P22455-1]
DR   CTD; 2264; -.
DR   DisGeNET; 2264; -.
DR   GeneCards; FGFR4; -.
DR   HGNC; HGNC:3691; FGFR4.
DR   HPA; ENSG00000160867; Tissue enhanced (liver, lung).
DR   MIM; 134935; gene.
DR   neXtProt; NX_P22455; -.
DR   OpenTargets; ENSG00000160867; -.
DR   PharmGKB; PA28130; -.
DR   VEuPathDB; HostDB:ENSG00000160867; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000161469; -.
DR   HOGENOM; CLU_000288_74_3_1; -.
DR   InParanoid; P22455; -.
DR   OMA; NRPFGRD; -.
DR   OrthoDB; 220433at2759; -.
DR   PhylomeDB; P22455; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P22455; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1307965; betaKlotho-mediated ligand binding.
DR   Reactome; R-HSA-1839128; FGFR4 mutant receptor activation.
DR   Reactome; R-HSA-190322; FGFR4 ligand binding and activation.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4.
DR   Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling.
DR   Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4.
DR   Reactome; R-HSA-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   SignaLink; P22455; -.
DR   SIGNOR; P22455; -.
DR   BioGRID-ORCS; 2264; 21 hits in 1111 CRISPR screens.
DR   ChiTaRS; FGFR4; human.
DR   GeneWiki; Fibroblast_growth_factor_receptor_4; -.
DR   GenomeRNAi; 2264; -.
DR   Pharos; P22455; Tclin.
DR   PRO; PR:P22455; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P22455; protein.
DR   Bgee; ENSG00000160867; Expressed in right lobe of liver and 110 other tissues.
DR   ExpressionAtlas; P22455; baseline and differential.
DR   Genevisible; P22455; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0030133; C:transport vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0055062; P:phosphate ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0070857; P:regulation of bile acid biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Endoplasmic reticulum; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           22..802
FT                   /note="Fibroblast growth factor receptor 4"
FT                   /id="PRO_0000016787"
FT   TOPO_DOM        22..369
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        370..390
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        391..802
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          22..118
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          152..240
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          249..349
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          467..755
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          119..148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        124..138
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        612
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         473..481
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         503
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         390
FT                   /note="Phosphotyrosine; in variant R-388"
FT                   /evidence="ECO:0000269|PubMed:26675719"
FT   MOD_RES         573
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         642
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18670643"
FT   MOD_RES         643
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18670643"
FT   MOD_RES         754
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:7518429"
FT   CARBOHYD        112
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        258
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        290
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        311
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        322
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        57..101
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        172..224
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        271..333
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         353..416
FT                   /note="EEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPA
FT                   TVQKLSRFPLAR -> GTGRIPHLTCDSLTPAGRTKSPTL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10631118"
FT                   /id="VSP_035108"
FT   VARIANT         10
FT                   /note="V -> I (in dbSNP:rs1966265)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:21882254, ECO:0000269|Ref.7"
FT                   /id="VAR_029185"
FT   VARIANT         136
FT                   /note="P -> L (in dbSNP:rs376618)"
FT                   /evidence="ECO:0000269|PubMed:10631118,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21882254,
FT                   ECO:0000269|Ref.6, ECO:0000269|Ref.7, ECO:0000269|Ref.9"
FT                   /id="VAR_042211"
FT   VARIANT         179
FT                   /note="T -> A (in dbSNP:rs55675160)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042212"
FT   VARIANT         388
FT                   /note="G -> R (in cancer cells, may be associated with
FT                   accelerated disease progression and increased tumor cell
FT                   motility, possibly due to increased stability of the
FT                   protease MMP14; leads to phosphorylation at residue Y-390,
FT                   resulting in prolonged FGFR4 activity; increases
FT                   interaction with STAT3, resulting in STAT3 phosphorylation
FT                   and signaling activation.; dbSNP:rs351855)"
FT                   /evidence="ECO:0000269|PubMed:18670643,
FT                   ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20876804,
FT                   ECO:0000269|PubMed:21349172, ECO:0000269|PubMed:21882254,
FT                   ECO:0000269|PubMed:26675719, ECO:0000269|Ref.7"
FT                   /id="VAR_014797"
FT   VARIANT         426
FT                   /note="G -> S (in dbSNP:rs55879131)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046102"
FT   VARIANT         516
FT                   /note="D -> N (in dbSNP:rs34158682)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042213"
FT   VARIANT         529
FT                   /note="R -> Q (in dbSNP:rs34284947)"
FT                   /id="VAR_049720"
FT   VARIANT         550
FT                   /note="V -> M (in breast pleomorphic lobular sample;
FT                   somatic mutation; dbSNP:rs774571806)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046103"
FT   VARIANT         712
FT                   /note="P -> T (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046104"
FT   VARIANT         772
FT                   /note="S -> N (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046105"
FT   MUTAGEN         503
FT                   /note="K->R: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11433297,
FT                   ECO:0000269|PubMed:17311277"
FT   MUTAGEN         754
FT                   /note="Y->F: Loss of interaction with PLCG1."
FT                   /evidence="ECO:0000269|PubMed:7518429"
FT   CONFLICT        121
FT                   /note="L -> S (in Ref. 3; AAF27432)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        194
FT                   /note="E -> G (in Ref. 3; AAF27432)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        297
FT                   /note="D -> V (in Ref. 1; CAA40490)"
FT                   /evidence="ECO:0000305"
FT   STRAND          145..150
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   HELIX           152..155
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          159..163
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          168..171
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          174..178
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          181..186
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   TURN            204..207
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          208..213
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   HELIX           216..218
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          220..227
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          232..242
FT                   /evidence="ECO:0007829|PDB:6J6Y"
FT   STRAND          259..262
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          267..271
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          280..286
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          292..294
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          296..298
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          302..310
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          316..320
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          329..336
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   STRAND          341..351
FT                   /evidence="ECO:0007829|PDB:7N1J"
FT   HELIX           445..448
FT                   /evidence="ECO:0007829|PDB:4QQ5"
FT   TURN            458..460
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          467..474
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          480..487
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          489..493
FT                   /evidence="ECO:0007829|PDB:6NVH"
FT   STRAND          497..504
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           511..527
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          531..533
FT                   /evidence="ECO:0007829|PDB:5XFJ"
FT   STRAND          536..540
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          542..544
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          547..551
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           558..563
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   TURN            570..572
FT                   /evidence="ECO:0007829|PDB:6YI8"
FT   TURN            577..580
FT                   /evidence="ECO:0007829|PDB:6JPE"
FT   HELIX           586..605
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           615..617
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          618..620
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          626..628
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   TURN            631..635
FT                   /evidence="ECO:0007829|PDB:4XCU"
FT   HELIX           637..639
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          642..644
FT                   /evidence="ECO:0007829|PDB:4UXQ"
FT   HELIX           652..655
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           658..663
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           668..683
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   STRAND          689..692
FT                   /evidence="ECO:0007829|PDB:6NVH"
FT   HELIX           695..703
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           716..725
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           730..732
FT                   /evidence="ECO:0007829|PDB:4QQT"
FT   HELIX           736..748
FT                   /evidence="ECO:0007829|PDB:4QQT"
SQ   SEQUENCE   802 AA;  87954 MW;  B22B259831BB889F CRC64;
     MRLLLALLGV LLSVPGPPVL SLEASEEVEL EPCLAPSLEQ QEQELTVALG QPVRLCCGRA
     ERGGHWYKEG SRLAPAGRVR GWRGRLEIAS FLPEDAGRYL CLARGSMIVL QNLTLITGDS
     LTSSNDDEDP KSHRDPSNRH SYPQQAPYWT HPQRMEKKLH AVPAGNTVKF RCPAAGNPTP
     TIRWLKDGQA FHGENRIGGI RLRHQHWSLV MESVVPSDRG TYTCLVENAV GSIRYNYLLD
     VLERSPHRPI LQAGLPANTT AVVGSDVELL CKVYSDAQPH IQWLKHIVIN GSSFGADGFP
     YVQVLKTADI NSSEVEVLYL RNVSAEDAGE YTCLAGNSIG LSYQSAWLTV LPEEDPTWTA
     AAPEARYTDI ILYASGSLAL AVLLLLAGLY RGQALHGRHP RPPATVQKLS RFPLARQFSL
     ESGSSGKSSS SLVRGVRLSS SGPALLAGLV SLDLPLDPLW EFPRDRLVLG KPLGEGCFGQ
     VVRAEAFGMD PARPDQASTV AVKMLKDNAS DKDLADLVSE MEVMKLIGRH KNIINLLGVC
     TQEGPLYVIV ECAAKGNLRE FLRARRPPGP DLSPDGPRSS EGPLSFPVLV SCAYQVARGM
     QYLESRKCIH RDLAARNVLV TEDNVMKIAD FGLARGVHHI DYYKKTSNGR LPVKWMAPEA
     LFDRVYTHQS DVWSFGILLW EIFTLGGSPY PGIPVEELFS LLREGHRMDR PPHCPPELYG
     LMRECWHAAP SQRPTFKQLV EALDKVLLAV SEEYLDLRLT FGPYSPSGGD ASSTCSSSDS
     VFSHDPLPLG SSSFPFGSGV QT
//
